Patents Assigned to Tel Hashomer Medical Research and Infrastructure and Services Ltd.
  • ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20180016338
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: September 26, 2017
    Publication date: January 18, 2018
    Applicants: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD., RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal MARKEL, Rona ORTENBERG, Jacob SCHACHTER
  • PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME
    Publication number: 20180016311
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7), and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 18, 2018
    Applicant: Tel Hashomer Medical Research, Infrastructure and Services Ltd.
    Inventors: Amir ZLOTKIN, Hen Kestenboim
  • METHODS OF PREDICTING CLINICAL COURSE AND TREATING MULTIPLE SCLEROSIS
    Publication number: 20170362657
    Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 21, 2017
    Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat ACHIRON, Michael GUREVICH
  • PREVENTING AND TREATING INFLAMMATORY SKIN DISEASES
    Publication number: 20170335328
    Abstract: The present invention relates to methods of treating, preventing, reducing the severity of, reducing the incidence of, delaying the onset of, or reducing pathogenesis of an inflammatory skin disease, condition or lesion in a human subject, which include the step of administering to the subject a therapeutically effective amount of mi RNA compositions. In addition, methods of this invention may be used to treat symptoms of inflammatory skin diseases and reduce and/or inhibit keratinocyte proliferation.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 23, 2017
    Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Yechezkel SIDI, Dror AVNI, Gali LERMAN
  • Isolated populations of renal stem cells and methods of isolating and using same
    Patent number: 9808488
    Abstract: Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: November 7, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Benjamin Dekel, Orit Harari-Steinberg
  • METHODS FOR EXPANDING T CELL POPULATIONS
    Publication number: 20170296584
    Abstract: The present invention provides methods for expanding populations of T cell. The present invention further provides pharmaceutical compositions comprising the expanded T cells, including, ?? T cells, and use thereof for treating infectious, autoimmune or malignant diseases.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 19, 2017
    Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ilan BANK, Michal BESSER, Victoria MARCU
  • RNA POLYMERASE I INHIBITORS AND USES THEREOF
    Publication number: 20170290842
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 12, 2017
    Applicant: Tel HaShomer Medical Research Infrastructure and Services, Ltd.
    Inventors: Anat ACHIRON, Roi MASHIACH, Michael GUREVICH
  • Compositions and methods for treating hematological malignancies
    Patent number: 9782387
    Abstract: A compound represented by Formula I is provided for use in the treatment of a hematological malignancy in a subject in need thereof. Also provided are compositions and kits which comprise the compound.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: October 10, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Merav Leiba, Gabriela Rozic
  • Peptides and compositions for prevention of cell adhesion and methods of using same
    Patent number: 9777050
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7), and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: October 3, 2017
    Assignee: TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Amir Zlotkin, Hen Kestenboim
  • Methods of reprogramming renal cells
    Patent number: 9770469
    Abstract: A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: September 26, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Benjamin Dekel, Orit Harari-Steinberg
  • Klotho variant polypeptides
    Patent number: 9771567
    Abstract: Disclosed are Klotho variant proteins in which residue Glu414 and/or residue Asp238 is substituted with an amino acid different than L-Glu or L-Asp, respectively, as well as polynucleotides encoding the variant proteins, and the use thereof in therapy, especially for the treatment of cancers, especially breast cancer and pancreatic cancer.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: September 26, 2017
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ido Wolf, Tamar Rubinek
  • Methods of predicting clinical course and treating multiple sclerosis
    Patent number: 9758831
    Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 12, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Michael Gurevich
  • METHODS FOR PREVENTING PREMATURE FOLLICLE ACTIVATION
    Publication number: 20170239333
    Abstract: Provided are compositions and methods for preventing premature follicle activation and loss induced by acute insults, such as, medical treatment, a disease or a disorder, thereby preserving fertility in a subject.
    Type: Application
    Filed: August 30, 2015
    Publication date: August 24, 2017
    Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Dror MEIROW, Hadassa RONESS
  • Compositions of aquatic origin for prevention of cell adhesion and methods of using same
    Patent number: 9737571
    Abstract: A composition comprising an extract from an aquatic organism is disclosed. The composition is capable of preventing adhesion of a cell to a surface and is devoid of cytotoxic or cytostatic activity. Medical devices comprising same and methods for preventing or treating a pathological infection using same are also disclosed.
    Type: Grant
    Filed: September 21, 2008
    Date of Patent: August 22, 2017
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Amir Zlotkin, Eliahu Zlotkin, Amir Zlotkin
  • Peptides and compositions for prevention of cell adhesion and methods of using same
    Patent number: 9732124
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: August 15, 2017
    Assignee: TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
    Inventor: Amir Zlotkin
  • METHODS FOR PREVENTING TRANSPLANTATION-INDUCED FOLLICLE ACTIVATION
    Publication number: 20170224780
    Abstract: Provided are compositions and methods for preventing premature follicle activation and loss induced by transplantation of ovaries or tissues derived from ovaries, thereby preserving fertility in a subject.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 10, 2017
    Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Dror MEIROW, Hadassa RONESS
  • SYSTEM AND METHOD FOR OBJECTIVE CHROMATIC PERIMETRY ANALYSIS USING PUPILLOMETER
    Publication number: 20170209038
    Abstract: The present invention relates to a system, device and a method for objective visual field testing and in particular, to such a system and method in which provides objective chromatic perimetry test or color vision test using a pupillometer.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 27, 2017
    Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Ygal Rotenstreich, Mordecai Rosner
  • Method and system for electron radiotherapy
    Patent number: 9711253
    Abstract: A radiotherapy system is disclosed. The radiotherapy system comprises an electron beam generator for generating an electron beam and a magnetic field generator for generating a magnetic field. In some embodiments of the present invention, the system further comprises a controller for controlling the electron beam and the magnetic field generators such that the electron beam is dynamically shifted and the magnetic field is dynamically redirected synchronously with the shifting.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: July 18, 2017
    Assignees: Tel HaShomer Medical Research Infrastructure and Services Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Dror Alezra, Eran Nardi, Sion Koren, Itzhak Orion
  • RNA polymerase I inhibitors and uses thereof
    Patent number: 9688697
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: June 27, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • System and method for objective chromatic perimetry analysis using pupillometer
    Patent number: 9655509
    Abstract: The present invention relates to a system, device and a method for objective visual field testing and in particular, to such a system and method in which provides objective chromatic perimetry test or color vision test using a pupillometer.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: May 23, 2017
    Assignee: Tel Hashomer Medical Research Infrastructure and Services, Ltd.
    Inventors: Ygal Rotenstreich, Mordecai Rosner